Dapolsertib
Dapolsertib is an investigational new drug that is being evaluated for the treatment of cancer.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Dapolsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is dual inhibitor of PIM family of serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3) that is being developed by Ryvu Therapeutics SA.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1323895883 under CC BY-SA 4.0; modifications have been made.